For research and educational purposes only. Not medical advice.
S-23 Reference
Educational, not medical advice reference for S-23: SARM; regulatory status, evidence posture, source review, and schedule notes. Also known as…
Reference summary
Preclinical rat work demonstrated reversible spermatogenesis suppression in animal models. Direct human clinical efficacy data were not located during review.
Regulatory and posture
- Categories
- SARM
- Aliases
- Non-steroidal SARM, Investigational male contraceptive SARM
- Evidence posture
- preclinical - FDA enforcement attention. Sold only as a research chemical, not for human consumption per legal seller terms. WADA-prohibited under category S1.2 at all times. Suppresses spermatogenesis in preclinical animal models - human male-contraceptive efficacy is unproven. No FDA-approved drug label.
- Regulatory status
- No FDA-approved S-23 drug label. WADA prohibits SARMs under category S1.2 at all times. FDA enforcement against SARMs sellers applies. S-23 has been studied as a candidate male contraceptive in preclinical animal literature.
- Content review status
- research reference